Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-6-19
pubmed:abstractText
The objective of this paper is to examine safety and tolerability data from a number of recently completed clinical trials with the novel, dual 5alpha-reductase inhibitor, dutasteride.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0302-2838
pubmed:author
pubmed:issnType
Print
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
82-8
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:12814679-3-Oxo-5-alpha-Steroid 4-Dehydrogenase, pubmed-meshheading:12814679-Aged, pubmed-meshheading:12814679-Aged, 80 and over, pubmed-meshheading:12814679-Azasteroids, pubmed-meshheading:12814679-Biopsy, Needle, pubmed-meshheading:12814679-Dose-Response Relationship, Drug, pubmed-meshheading:12814679-Double-Blind Method, pubmed-meshheading:12814679-Drug Administration Schedule, pubmed-meshheading:12814679-Drug Interactions, pubmed-meshheading:12814679-Drug Therapy, Combination, pubmed-meshheading:12814679-Follow-Up Studies, pubmed-meshheading:12814679-Humans, pubmed-meshheading:12814679-Male, pubmed-meshheading:12814679-Middle Aged, pubmed-meshheading:12814679-Prostatic Hyperplasia, pubmed-meshheading:12814679-Randomized Controlled Trials as Topic, pubmed-meshheading:12814679-Risk Assessment, pubmed-meshheading:12814679-Treatment Outcome
pubmed:year
2003
pubmed:articleTitle
Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia.
pubmed:affiliation
Division of Urologic Surgery, Washington University School of Medicine, 4960 Children's Place, Campus Box 8242, St. Louis, MO 63110, USA. andrioleg@msnotes.wustl.edu
pubmed:publicationType
Journal Article, Comparative Study, Review